Clearpoint Stock Based Compensation from 2010 to 2024

CLPT Stock

USD 15.33 1.07 6.52%

Clearpoint Neuro Stock Based Compensation yearly trend continues to be comparatively stable with very little volatility. Stock Based Compensation is likely to outpace its year average in 2024. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals

Stock Based Compensation

First Reported

2011-09-30

Previous Quarter

1.8 M

Current Value

1.9 M

Quarterly Volatility

492.1 K

Yuan Drop

Covid

Check Clearpoint Neuro financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Clearpoint Neuro's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.5 M, Interest Expense of 366.7 K or Selling General Administrative of 7.5 M, as well as many indicators such as Price To Sales Ratio of 7.13, Dividend Yield of 0.0 or PTB Ratio of 8.29. Clearpoint financial statements analysis is a perfect complement when working with Clearpoint Neuro Valuation or Volatility modules.

Check out the analysis of Clearpoint Neuro Correlation against competitors.

For more information on how to buy Clearpoint Stock please use our How to Invest in Clearpoint Neuro guide.

Latest Clearpoint Neuro's Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of Clearpoint Neuro over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Clearpoint Neuro's Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Clearpoint Neuro's overall financial position and show how it may be relating to other accounts over time.

Stock Based Compensation

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Stock Based Compensation

Timeline

Clearpoint Stock Based Compensation Regression Statistics

	Arithmetic Mean	2,085,292
	Geometric Mean	1,503,789
	Coefficient Of Variation	91.10
	Mean Deviation	1,377,610
	Median	1,245,601
	Standard Deviation	1,899,715
	Sample Variance	3.6T
	Range	6.1M
	R-Value	0.72
	Mean Square Error	1.9T
	R-Squared	0.52
	Significance	0
	Slope	305,654
	Total Sum of Squares	50.5T

Clearpoint Stock Based Compensation History

	2024	6.4 M
	2023	6.1 M
	2022	4.1 M
	2021	2.1 M
	2020	1.1 M
	2019	799.1 K
	2018	1.2 M

Other Fundumenentals of Clearpoint Neuro

Stock Based Compensation To Revenue

Clearpoint Neuro Stock Based Compensation component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Retained Earnings	Intangible Assets	Long Term Debt	Long Term Debt Total	Capital Surpluse	Property Plant Equipment	Net Tangible Assets	Net Invested Capital	Short Long Term Debt	Net Working Capital	Capital Stock	Deferred Long Term Liab
Total Assets		0.92	0.07	-0.87	-0.59	0.69	0.28	1.0	-0.43	-0.14	0.42	-0.01	0.61	0.62	0.9	0.76	0.86	0.96	-0.19	0.97	0.91	0.69
Total Stockholder Equity	0.92		-0.04	-0.92	-0.74	0.74	-0.06	0.93	-0.53	-0.12	0.59	-0.16	0.42	0.43	0.85	0.61	0.88	0.88	-0.32	0.89	0.86	0.64
Current Deferred Revenue	0.07	-0.04		0.01	0.3	0.43	0.58	0.05	0.0	-0.36	-0.46	0.77	0.08	0.1	0.31	0.08	0.4	0.17	-0.6	0.17	0.38	0.48
Net Debt	-0.87	-0.92	0.01		0.51	-0.54	0.03	-0.89	0.38	0.14	-0.41	0.19	-0.27	-0.27	-0.74	-0.58	-0.83	-0.87	0.17	-0.88	-0.75	-0.45
Accounts Payable	-0.59	-0.74	0.3	0.51		-0.67	0.3	-0.59	0.68	0.07	-0.78	0.42	-0.46	-0.46	-0.61	-0.49	-0.53	-0.46	0.3	-0.48	-0.58	-0.43
Net Receivables	0.69	0.74	0.43	-0.54	-0.67		0.23	0.67	-0.47	-0.17	0.46	0.17	0.54	0.56	0.84	0.55	0.88	0.68	-0.79	0.68	0.88	0.84
Total Liab	0.28	-0.06	0.58	0.03	0.3	0.23		0.26	0.22	-0.1	-0.37	0.51	0.61	0.62	0.24	0.51	0.21	0.37	-0.14	0.35	0.34	0.3
Total Current Assets	1.0	0.93	0.05	-0.89	-0.59	0.67	0.26		-0.43	-0.14	0.43	-0.04	0.58	0.59	0.89	0.75	0.85	0.97	-0.17	0.97	0.9	0.66
Short Term Debt	-0.43	-0.53	0.0	0.38	0.68	-0.47	0.22	-0.43		0.63	-0.35	0.12	-0.42	-0.42	-0.56	-0.47	-0.4	-0.32	0.17	-0.36	-0.5	-0.32
Common Stock	-0.14	-0.12	-0.36	0.14	0.07	-0.17	-0.1	-0.14	0.63		0.08	-0.14	-0.2	-0.2	-0.3	-0.21	-0.2	-0.14	0.08	-0.16	-0.23	-0.13
Retained Earnings	0.42	0.59	-0.46	-0.41	-0.78	0.46	-0.37	0.43	-0.35	0.08		-0.72	0.27	0.27	0.41	0.3	0.34	0.27	-0.18	0.29	0.37	0.26
Intangible Assets	-0.01	-0.16	0.77	0.19	0.42	0.17	0.51	-0.04	0.12	-0.14	-0.72		-0.02	0.0	0.16	-0.14	0.19	0.1	-0.29	0.08	0.2	0.45
Long Term Debt	0.61	0.42	0.08	-0.27	-0.46	0.54	0.61	0.58	-0.42	-0.2	0.27	-0.02		1.0	0.52	0.89	0.4	0.58	-0.19	0.58	0.6	0.36
Long Term Debt Total	0.62	0.43	0.1	-0.27	-0.46	0.56	0.62	0.59	-0.42	-0.2	0.27	0.0	1.0		0.55	0.89	0.42	0.58	-0.2	0.58	0.62	0.4
Capital Surpluse	0.9	0.85	0.31	-0.74	-0.61	0.84	0.24	0.89	-0.56	-0.3	0.41	0.16	0.52	0.55		0.62	0.9	0.83	-0.4	0.84	0.95	0.88
Property Plant Equipment	0.76	0.61	0.08	-0.58	-0.49	0.55	0.51	0.75	-0.47	-0.21	0.3	-0.14	0.89	0.89	0.62		0.57	0.74	-0.17	0.76	0.71	0.32
Net Tangible Assets	0.86	0.88	0.4	-0.83	-0.53	0.88	0.21	0.85	-0.4	-0.2	0.34	0.19	0.4	0.42	0.9	0.57		0.88	-0.61	0.88	0.94	0.81
Net Invested Capital	0.96	0.88	0.17	-0.87	-0.46	0.68	0.37	0.97	-0.32	-0.14	0.27	0.1	0.58	0.58	0.83	0.74	0.88		-0.25	1.0	0.89	0.64
Short Long Term Debt	-0.19	-0.32	-0.6	0.17	0.3	-0.79	-0.14	-0.17	0.17	0.08	-0.18	-0.29	-0.19	-0.2	-0.4	-0.17	-0.61	-0.25		-0.25	-0.5	-0.56
Net Working Capital	0.97	0.89	0.17	-0.88	-0.48	0.68	0.35	0.97	-0.36	-0.16	0.29	0.08	0.58	0.58	0.84	0.76	0.88	1.0	-0.25		0.9	0.64
Capital Stock	0.91	0.86	0.38	-0.75	-0.58	0.88	0.34	0.9	-0.5	-0.23	0.37	0.2	0.6	0.62	0.95	0.71	0.94	0.89	-0.5	0.9		0.85
Deferred Long Term Liab	0.69	0.64	0.48	-0.45	-0.43	0.84	0.3	0.66	-0.32	-0.13	0.26	0.45	0.36	0.4	0.88	0.32	0.81	0.64	-0.56	0.64	0.85

Click cells to compare fundamentals

About Clearpoint Neuro Financial Statements

Clearpoint Neuro shareholders use historical fundamental indicators, such as Stock Based Compensation, to determine how well the company is positioned to perform in the future. Although Clearpoint Neuro investors may analyze each financial statement separately, they are all interrelated. The changes in Clearpoint Neuro's assets and liabilities, for example, are also reflected in the revenues and expenses on on Clearpoint Neuro's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Stock Based Compensation	6.1 M	6.4 M
Stock Based Compensation To Revenue	0.25	0.23

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Clearpoint Stock Analysis

When running Clearpoint Neuro's price analysis, check to measure Clearpoint Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearpoint Neuro is operating at the current time. Most of Clearpoint Neuro's value examination focuses on studying past and present price action to predict the probability of Clearpoint Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearpoint Neuro's price. Additionally, you may evaluate how the addition of Clearpoint Neuro to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Clearpoint Stock Based Compensation from 2010 to 2024

Latest Clearpoint Neuro's Stock Based Compensation Growth Pattern

Clearpoint Stock Based Compensation Regression Statistics

Clearpoint Stock Based Compensation History

Other Fundumenentals of Clearpoint Neuro

Clearpoint Neuro Stock Based Compensation component correlations

About Clearpoint Neuro Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Clearpoint Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY